Diabetes and Cardiovascular Disease: an Update (original) (raw)
Papers of particular interest, published recently, have been highlighted as: • Of importance •• Of major importance
Control CfD, Prevention. National diabetes statistics report, 2017. Atlanta: Centers for Disease Control and Prevention; 2017. Google Scholar
Association AD. Economic costs of diabetes in the US in 2017. Diabetes Care. 2018;41(5):917–28. Google Scholar
Booth GL, Kapral MK, Fung K, Tu JV. Relation between age and cardiovascular disease in men and women with diabetes compared with non-diabetic people: a population-based retrospective cohort study. Lancet. 2006;368(9529):29–36. PubMed Google Scholar
Lee WL, Cheung AM, Cape D, Zinman B. Impact of diabetes on coronary artery disease in women and men: a meta-analysis of prospective studies. Diabetes Care. 2000;23(7):962–8. CASPubMed Google Scholar
Stamler J, Vaccaro O, Neaton JD, Wentworth D, Group MRFITR. Diabetes, other risk factors, and 12-yr cardiovascular mortality for men screened in the multiple risk factor intervention trial. Diabetes Care. 1993;16(2):434–44. CASPubMed Google Scholar
Sowers JR. Obesity as a cardiovascular risk factor. Am J Med. 2003;115(8):37–41. Google Scholar
Randle P, Garland P, Hales C, Newsholme E. The glucose fatty-acid cycle its role in insulin sensitivity and the metabolic disturbances of diabetes mellitus. Lancet. 1963;281(7285):785–9. Google Scholar
Mooradian AD. Dyslipidemia in type 2 diabetes mellitus. Nat Rev Endocrinol. 2009;5(3):150–9. CAS Google Scholar
Lumeng CN, Bodzin JL, Saltiel AR. Obesity induces a phenotypic switch in adipose tissue macrophage polarization. J Clin Invest. 2007;117(1):175–84. CASPubMedPubMed Central Google Scholar
De Pergola G, De Mitrio V, Giorgino F, Sciaraffia M, Minenna A, Di Bari L, et al. Increase in both pro-thrombotic and anti-thrombotic factors in obese premenopausal women: relationship with body fat distribution. Int J Obes. 1997;21(7):527–35. Google Scholar
Aroor AR, DeMarco V, Jia G, Sun Z, Nistala R, Meininger GA, et al. The role of tissue renin-angiotensin-aldosterone system in the development of endothelial dysfunction and arterial stiffness. Front Endocrinol. 2013;4:161. Google Scholar
Sowers JR. Hypertension and vascular disease. Hypertension. 2013;61(5):943–7. CASPubMed Google Scholar
Vanessa Fiorentino T, Prioletta A, Zuo P, Folli F. Hyperglycemia-induced oxidative stress and its role in diabetes mellitus related cardiovascular diseases. Curr Pharm Des. 2013;19(32):5695–703. Google Scholar
Li Q, Verma IM. NF-κB regulation in the immune system. Nat Rev Immunol. 2002;2(10):725–34. CASPubMed Google Scholar
Adhikari N, Basi DL, Carlson M, Mariash A, Hong Z, Lehman U, et al. Increase in GLUT1 in smooth muscle alters vascular contractility and increases inflammation in response to vascular injury. Arterioscler Thromb Vasc Biol. 2011;31(1):86–94. CASPubMed Google Scholar
Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, et al. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest. 1977;60(4):885–99. PubMed Central Google Scholar
Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol. 1972;30(6):595–602. CASPubMed Google Scholar
Mizushige K, Yao L, Noma T, Kiyomoto H, Yu Y, Hosomi N, et al. Alteration in left ventricular diastolic filling and accumulation of myocardial collagen at insulin-resistant prediabetic stage of a type II diabetic rat model. Circulation. 2000;101(8):899–907. CASPubMed Google Scholar
•• Jia G, Hill MA, Sowers JR. Diabetic cardiomyopathy: an update of mechanisms contributing to this clinical entity. Circ Res. 2018;122(4):624–38. Diabetic cardiomyopathy can occur in patients without coronary artery disease or other conventional risk factors. This review discusses mechanisms for diabetic cardiomyopathy and stratifies for prevention and treatment. CASPubMedPubMed Central Google Scholar
Fang ZY, Prins JB, Marwick TH. Diabetic cardiomyopathy: evidence, mechanisms, and therapeutic implications. Endocr Rev. 2004;25(4):543–67. CASPubMed Google Scholar
•• Care D. Standards of medical care in diabetes 2019. Diabetes Care. 2019;42:S81. Annual update from American Diabetes Association gives current guidelines and changes for the year regarding the care for patients with diabetes. Google Scholar
•• Garber AJ, Abrahamson MJ, Barzilay JI, Blonde L, Bloomgarden ZT, Bush MA, et al. Consensus statement by the American association of clinical endocrinologists and American college of endocrinology on the comprehensive type 2 diabetes management algorithm–2019 executive summary. Endoc Pract. 2019;25(1):69–100. Important management algorithm that guides evidence-based patient care. Google Scholar
Group DPPR. The diabetes prevention program (DPP): description of lifestyle intervention. Diabetes Care. 2002;25(12):2165–71. Google Scholar
Group LAR. Eight-year weight losses with an intensive lifestyle intervention: the look AHEAD study. Obesity. 2014;22(1):5–13. Google Scholar
Salas-Salvadó J, Díaz-López A, Ruiz-Canela M, Basora J, Fitó M, Corella D, et al. Effect of a lifestyle intervention program with energy-restricted mediterranean diet and exercise on weight loss and cardiovascular risk factors: one-year results of the PREDIMED-plus trial. Diabetes Care. 2019;42(5):777–88. PubMed Google Scholar
Lean ME, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, et al. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. Lancet. 2018;391(10120):541–51. PubMed Google Scholar
Control D, Group CTR. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 1993;329(14):977–86. Google Scholar
Cleary PA, Orchard TJ, Genuth S, Wong ND, Detrano R, Backlund J-YC, et al. The effect of intensive glycemic treatment on coronary artery calcification in type 1 diabetic participants of the diabetes Control and complications trial/epidemiology of diabetes interventions and complications (DCCT/EDIC) study. Diabetes. 2006;55(12):3556–65. CASPubMed Google Scholar
King P, Peacock I, Donnelly R. The UK prospective diabetes study (UKPDS): clinical and therapeutic implications for type 2 diabetes. Br J Clin Pharmacol. 1999;48(5):643–8. CASPubMedPubMed Central Google Scholar
Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HAW. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359(15):1577–89. CASPubMed Google Scholar
Genuth S, Eastman R, Kahn R, Klein R, Lachin J, Lebovitz H, et al. Implications of the United Kingdom prospective diabetes study. Diabetes Care. 2003;26:S28. PubMed Google Scholar
Gæde P, Vedel P, Parving H-H, Pedersen O. Intensified multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: the Steno type 2 randomised study. Lancet. 1999;353(9153):617–22. PubMed Google Scholar
Gæde P, Oellgaard J, Carstensen B, Rossing P, Lund-Andersen H, Parving H-H, et al. Years of life gained by multifactorial intervention in patients with type 2 diabetes mellitus and microalbuminuria: 21 years follow-up on the Steno-2 randomised trial. Diabetologia. 2016;59(11):2298–307. PubMedPubMed Central Google Scholar
Group AC. Intensive blood glucose control and vascular outcomes in patients with type 2 diabetes. N Engl J Med. 2008;358(24):2560–72. Google Scholar
Group AtCCRiDS. Effects of intensive glucose lowering in type 2 diabetes. N Engl J Med. 2008;358(24):2545–59. Google Scholar
Duckworth W, Abraira C, Moritz T, Reda D, Emanuele N, Reaven PD, et al. Glucose control and vascular complications in veterans with type 2 diabetes. N Engl J Med. 2009;360(2):129–39. CASPubMed Google Scholar
• Reaven PD, Emanuele NV, Wiitala WL, Bahn GD, Reda DJ, McCarren M, et al. Intensive glucose control in patients with type 2 diabetes—15-year follow-up. NEJM. 2019;380:2215–24. https://doi.org/10.1056/NEJMoa1806802. Important follow-up trial that did not show metabolic memory of legacy effect as oppsed to DCCT and UKPDS long-term trials. ArticleCASPubMed Google Scholar
Investigators OT. Rationale, design, and baseline characteristics for a large international trial of cardiovascular disease prevention in people with dysglycemia: the ORIGIN Trial (Outcome Reduction with an Initial Glargine Intervention). Am Heart J. 2008;155(1):26. e1–e13. Google Scholar
Turnbull F, Abraira C, Anderson RJ, Byington R, Chalmers J, Duckworth W, et al. Intensive glucose control and macrovascular outcomes in type 2 diabetes. Berlin: Springer; 2009. Google Scholar
Merino J, Leong A, Posner DC, Porneala B, Masana L, Dupuis J, et al. Genetically driven hyperglycemia increases risk of coronary artery disease separately from type 2 diabetes. Diabetes Care. 2017;40(5):687–93. CASPubMedPubMed Central Google Scholar
Zinman B, Wanner C, Lachin JM, Fitchett D, Bluhmki E, Hantel S, et al. Empagliflozin, cardiovascular outcomes, and mortality in type 2 diabetes. N Engl J Med. 2015;373(22):2117–28. CASPubMed Google Scholar
Neal B, Perkovic V, Mahaffey KW, De Zeeuw D, Fulcher G, Erondu N, et al. Canagliflozin and cardiovascular and renal events in type 2 diabetes. N Engl J Med. 2017;377(7):644–57. CASPubMed Google Scholar
Wiviott SD, Raz I, Bonaca MP, Mosenzon O, Kato ET, Cahn A, et al. Dapagliflozin and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2019;380(4):347–57. CASPubMed Google Scholar
Pfeffer MA, Claggett B, Diaz R, Dickstein K, Gerstein HC, Køber LV, et al. Lixisenatide in patients with type 2 diabetes and acute coronary syndrome. N Engl J Med. 2015;373(23):2247–57. CASPubMed Google Scholar
Marso SP, Daniels GH, Brown-Frandsen K, Kristensen P, Mann JF, Nauck MA, et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2016;375(4):311–22. CASPubMedPubMed Central Google Scholar
Marso SP, Bain SC, Consoli A, Eliaschewitz FG, Jódar E, Leiter LA, et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2016;375(19):1834–44. CASPubMed Google Scholar
Husain M, Birkenfeld AL, Donsmark M, Dungan K, Eliaschewitz FG, Franco DR, et al. Oral Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. N Engl J Med. 2019;381:841–51. CASPubMed Google Scholar
Holman RR, Bethel MA, Mentz RJ, Thompson VP, Lokhnygina Y, Buse JB, et al. Effects of once-weekly exenatide on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2017;377(13):1228–39. CASPubMed Google Scholar
Bhatt DL, editor. Saxagliptin Assessment of Vascular Outcomes Recorded in patients with diabetes mellitus (SAVOR)–TIMI 53. Presentation delivered at the European Association for the Study of Diabetes 49th annual meeting on; 2013.
•• Cutshall BT, Twilla JD, Olinger AS, Oliphant CS. A review on cardiovascular effects of newer hypoglycaemic medications. Ann Med. 2017;49(7):603–12. Reviews the importance of selecting medications that provide diabetes control while maintaining cardiovascular safety. CASPubMed Google Scholar
White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, et al. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med. 2013;369(14):1327–35. CASPubMed Google Scholar
Green JB, Bethel MA, Armstrong PW, Buse JB, Engel SS, Garg J, et al. Effect of sitagliptin on cardiovascular outcomes in type 2 diabetes. N Engl J Med. 2015;373(3):232–42. CASPubMed Google Scholar
Association AD. 10. Cardiovascular disease and risk management: standards of medical care in diabetes—2019. Diab Care. 2019;42(Supplement 1):S103–S23. Google Scholar
Colhoun HM, Betteridge DJ, Durrington PN, Hitman GA, Neil HAW, Livingstone SJ, et al. Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the collaborative atorvastatin diabetes study (CARDS): multicentre randomised placebo-controlled trial. Lancet. 2004;364(9435):685–96. CASPubMed Google Scholar
Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med. 2004;350(15):1495–504. CASPubMed Google Scholar
Group AS. Effects of combination lipid therapy in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1563–74. Google Scholar
Cannon CP, Blazing MA, Giugliano RP, McCagg A, White JA, Theroux P, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med. 2015;372(25):2387–97. CASPubMed Google Scholar
• Ghadban R, Enezate T, Omran J, Almourani R, Singla A, Balla S. Clinical outcomes of PCSK9Is: a meta-analysis of randomized clinical trials. Cardiovasc Diag Ther. 2017;7(6):598–606. This meta-analysis shows the importance of PCSK9 inhibitors in improving clinical outcomes in patients at high risk for atherosclerotic cardiovascular disease. Google Scholar
Sabatine MS, Giugliano RP, Keech AC, Honarpour N, Wiviott SD, Murphy SA, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med. 2017;376(18):1713–22. CASPubMed Google Scholar
Handelsman Y, Lepor NE. PCSK9 inhibitors in lipid management of patients with diabetes mellitus and high cardiovascular risk: a review. J Am Heart Assoc. 2018;7(13):e008953. PubMedPubMed Central Google Scholar
Giugliano RP, Pedersen TR, Park J-G, De Ferrari GM, Gaciong ZA, Ceska R, et al. Clinical efficacy and safety of achieving very low LDL-cholesterol concentrations with the PCSK9 inhibitor evolocumab: a prespecified secondary analysis of the FOURIER trial. Lancet. 2017;390(10106):1962–71. CASPubMed Google Scholar
Lastra G, Syed S, Kurukulasuriya LR, Manrique C, Sowers JR. Type 2 diabetes mellitus and hypertension: an update. Endocrinol Metab Clin. 2014;43(1):103–22. Google Scholar
Jia G, Aroor AR, Martinez-Lemus LA, Sowers JR. Potential role of antihypertensive medications in preventing excessive arterial stiffening. Curr Hypertens Rep. 2018;20(9):76. PubMedPubMed Central Google Scholar
James PA, Oparil S, Carter BL, Cushman WC, Dennison-Himmelfarb C, Handler J, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth joint National Committee (JNC 8). Jama. 2014;311(5):507–20. CASPubMed Google Scholar
Group AS. Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med. 2010;362(17):1575–85. Google Scholar
Cushman WC, Evans GW, Cutler JA. Long-term cardiovascular effects of 4.9 years of intensive blood pressure control in type 2 diabetes mellitus: the action to control cardiovascular risk in diabetes follow-on blood-pressure study. Am Heart Assoc. 2015.
Group SR. A randomized trial of intensive versus standard blood-pressure control. N Engl J Med. 2015;373(22):2103–16. Google Scholar
Margolis KL, O’Connor PJ, Morgan TM, Buse JB, Cohen RM, Cushman WC, et al. Outcomes of combined cardiovascular risk factor management strategies in type 2 diabetes: the ACCORD randomized trial. Diabetes Care. 2014;37(6):1721–8. CASPubMedPubMed Central Google Scholar
• Whaley-Connell A, Sowers JR. Blood pressure related outcomes in a diabetic population. Hypertension. 2016;68(1):34. Evidence-based review of BP control in patients with diabetes. CASPubMed Google Scholar
Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A. Blood pressure lowering in type 2 diabetes: a systematic review and meta-analysis. Jama. 2015;313(6):603–15. PubMed Google Scholar
Wu Z, Jin C, Vaidya A, Jin W, Huang Z, Wu S, et al. Longitudinal patterns of blood pressure, incident cardiovascular events, and all-cause mortality in normotensive diabetic people. Hypertension. 2016;68(1):71–7. CASPubMed Google Scholar
•• Rahman F, McEvoy JW, Ohkuma T, Marre M, Hamet P, Harrap S, et al. Effects of blood pressure lowering on clinical outcomes according to baseline blood pressure and cardiovascular risk in patients with type 2 diabetes mellitus: the ADVANCE trial. Hypertension. 2019:HYPERTENSIONAHA.118.12414. This study shows that adults with DM appear to benefit from more intensive BP management than what current guidelines recommend.
Zoungas S, Chalmers J, Bruce N, Billot Laurent , Li Q, et al ADVANCE On Collaborative group- Follow uo of Blood pressure 2 Lowering and glucose control in Type 2 diabetes New Eng J Med 2014;371:1392-1406
Investigators O. Telmisartan, ramipril, or both in patients at high risk for vascular events. N Engl J Med. 2008;358(15):1547–59. Google Scholar
• Perkovic V, Jardine MJ, Neal B, Bompoint S, Heerspink HJ, Charytan DM, et al. Canagliflozin and renal outcomes in type 2 diabetes and nephropathy. New Engl J Med. 2019. Effect of an antidiabetic agent on reducing the risks of kidney disease and cardiovascular events.
• Baigent C, Blackwell L, Collins R, Emberson J, Godwin J, Peto R, et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Elsevier; 2009. Strong message about aspirin in primary prevention. Aaspirin is of uncertain net value as the reduction in occlusive events needs to be weighed against any increase in major bleeds.
Gaziano JM, Brotons C, Coppolecchia R, Cricelli C, Darius H, Gorelick PB, et al. Use of aspirin to reduce risk of initial vascular events in patients at moderate risk of cardiovascular disease (ARRIVE): a randomised, double-blind, placebo-controlled trial. Lancet. 2018;392(10152):1036–46. CASPubMedPubMed Central Google Scholar
McNeil JJ, Nelson MR, Woods RL, Lockery JE, Wolfe R, Reid CM, et al. Effect of aspirin on all-cause mortality in the healthy elderly. N Engl J Med. 2018;379(16):1519–28. CASPubMedPubMed Central Google Scholar
Mcneil J, Wolfe R, Woods, R, Tonkin A, Geoffrey A et al ASPree investigator group. Effect of Aspirin on cardiovascular events and bleeding in the healthy Elderly New End J Med 2018 379:1509-1518
Beck RW, Riddlesworth T, Ruedy K, Ahmann A, Bergenstal R, Haller S, et al. Effect of continuous glucose monitoring on glycemic control in adults with type 1 diabetes using insulin injections: the DIAMOND randomized clinical trial. Jama. 2017;317(4):371–8. CASPubMed Google Scholar
Zhou JJ, Koska J, Bahn G, Reaven P. Glycaemic variation is a predictor of all-cause mortality in the veteran affairs diabetes trial. Diabetes and Vascular Disease Research. 2019;16(2):178–85. PubMed Google Scholar